TY - JOUR T1 - PARP Inhibitors in Prostate Cancer JF - Anticancer Research JO - Anticancer Res SP - 551 LP - 556 DO - 10.21873/anticanres.14807 VL - 41 IS - 2 AU - KABIR GREWAL AU - KAYANAAT GREWAL AU - IMAD A. TABBARA Y1 - 2021/02/01 UR - http://ar.iiarjournals.org/content/41/2/551.abstract N2 - Treatment of metastatic prostate cancer has evolved significantly over the past decade. Palliative therapy has, historically, consisted of androgen deprivation, chemotherapy and different radiation therapy approaches. More recently, breakthrough therapy with the use of poly-ADP-ribose polymerase (PARP) inhibitors has led to significant improvement in the outcome of patients with metastatic prostate cancer who harbor certain genetic mutations. This concise review focuses on the 3 PARP inhibitors that have shown activity in metastatic prostate cancer. ER -